MYC and breast carcinoma: Our previous studies in ER-positive breast cancer also revealed that ARV-825 treatment successfully downregulated BRD4 and c-Myc expression and prolonged growth arrest while further sensitizing breast cancer cells to palbociclib + fulvestrant treatment [34,35].